Evidence map›Paper›PMID 41835019›Full record

ArticleReinforcement learning journal2025

When and Why Hyperbolic Discounting Matters for Reinforcement Learning Interventions.

Ian M Moore, Eura Nofshin, Siddharth Swaroop, Susan Murphy, Finale Doshi-Velez, Weiwei Pan

Abstract read
In one paragraph

Article in Reinforcement learning journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ian M MooreDepartment of Computer Science, Harvard University, USA.
Eura NofshinDepartment of Computer Science, Harvard University, USA.
Siddharth SwaroopDepartment of Computer Science, Harvard University, USA.
Susan MurphyDepartment of Computer Science, Harvard University, USA.
Finale Doshi-VelezDepartment of Computer Science, Harvard University, USA.
Weiwei PanDepartment of Computer Science, Harvard University, USA.

Funding

TR&D3 - Rapid Translation of AI-powered Temporally Precise mHealth Interventions via Efficient and Embeddable Trustworthy Biomarker ImplementationsP41EB028242 · NIBIB · UNIVERSITY OF MEMPHIS · PI Santosh Kumar · 2020 to 2026
$9.5M
NIBIB NIH HHS P41 EB028242
6 · The paper itself

Abstract

In settings where an AI agent nudges a human agent toward a goal, the quality of the AI's policy depends on how well it models the human. Despite behavioral evidence that humans hyperbolically discount future rewards, the RL community continues to model humans as Markov Decision Processes (MDPs) with exponential discounting. This is because planning is difficult with non-exponential discounts. In this work, we investigate whether the performance benefits of modeling humans as hyperbolic discounters outweigh the computational costs. We focus on AI interventions that change the human's discounting (i.e. decreases the human's "nearsightedness" to help them toward distant goals). We derive a fixed exponential discount factor that can approximate hyperbolic discounting, and prove that this approximation guarantees the AI will never miss a necessary intervention. We also prove that our approximation causes fewer false positives (unnecessary interventions) than the mean hazard rate, another well-known method for approximating hyperbolic MDPs as exponential ones. Surprisingly, our experiments demonstrate that exponential approximations outperform hyperbolic ones in online learning, even when the ground-truth human MDP is hyperbolically discounted.

Indexed as

Agent-based modeling of humansHuman-AI interactionHyperbolic discounting

Identifiers

PMID41835019
PMCPMC12987681

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.